• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

罕见病——罕见结局:发育性和癫痫性脑病的沟通能力评估。

Rare diseases - rare outcomes: Assessing communication abilities for the developmental and epileptic encephalopathies.

机构信息

Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

出版信息

Epilepsy Behav. 2022 Mar;128:108586. doi: 10.1016/j.yebeh.2022.108586. Epub 2022 Feb 11.

DOI:10.1016/j.yebeh.2022.108586
PMID:35158285
Abstract

OBJECTIVE

Developmental and epileptic encephalopathies (DEE) entail moderate to profound communication and other impairments that are poorly measured by typical clinical outcomes assessments (COA). We examined the potential of alternative approaches, specifically, the use of raw scores and COAs outside of their intended age ranges.

METHODS

In a cross-sectional survey, 120 parents of children with Dravet Syndrome, Lennox-Gastaut syndrome, KCNQ2-DEE, KCNB1-DEE, and SCN2A-DEE (ages 1-35 years) completed the Adaptive Behavior Assessment System-3 for ages 0-5 years, modified checklist for autism (mCHAT), communication and social behavior scales (CSBS), communication matrix (CM), and several parent-reported classifiers of communication. Adaptive Behavior Assessment System communication and social raw scores were the primary and adjunctive outcomes. Floor and ceiling effects, dispersion and convergence with related measures were assessed with appropriate parametric and nonparametric statistical techniques.

RESULTS

Median chronological age (CA) was 8.7 years (Interquartile range (IQR): 5.3-13.5). Adaptive Behavior Assessment Systemcommunication and social age equivalents were 12.5 months (IQR 7.5-28) and 16.5 months (IQR 9-31). Most raw scores corresponded to standardized scores indicating performance <3 standard deviations below the general population mean. Adaptive Behavior Assessment System raw scores demonstrated minimal floor and ceiling effects (<1-2.5%). In linear regression models, scores correlated with age under 6 years (communication, p = 0.001; social, p = 0.003) but significantly flattened out thereafter. Scores varied substantially by DEE group (both p < 0.001) and decreased with higher convulsive seizure frequency (communication, p = 0.01, social, p = 0.02). There was good convergence with mCHAT, CSBS, and CM scores (all r > 0.8).

SIGNIFICANCE

Raw scores and out-of-range COAs may provide measures that are sensitive at the very limited levels of functioning typical of profoundly impaired, older patients with DEEs. To ensure that targeted trial outcomes are responsive to meaningful change, development of these approaches will be essential to clinical trial readiness for novel therapies for rare DEEs.

摘要

目的

发育性和癫痫性脑病(DEE)需要中度至重度的交流和其他障碍,这些障碍用典型的临床结果评估(COA)很难衡量。我们研究了替代方法的潜力,特别是在其预期年龄范围之外使用原始分数和 COA。

方法

在一项横断面调查中,120 名患有德拉维特综合征、 Lennox-Gastaut 综合征、KCNQ2-DEE、KCNB1-DEE 和 SCN2A-DEE 的儿童的父母(年龄 1-35 岁)完成了适用于 0-5 岁的适应性行为评估系统-3、改良自闭症检查表(mCHAT)、沟通和社会行为量表(CSBS)、沟通矩阵(CM)以及几个家长报告的沟通分类器。适应性行为评估系统沟通和社会原始分数是主要和辅助结果。使用适当的参数和非参数统计技术评估地板和天花板效应、与相关测量值的离散度和收敛性。

结果

中位年龄(CA)为 8.7 岁(四分位距(IQR):5.3-13.5)。适应性行为评估系统沟通和社会年龄等价物分别为 12.5 个月(IQR 7.5-28)和 16.5 个月(IQR 9-31)。大多数原始分数与标准化分数相对应,表明表现低于一般人群平均值 3 个标准差以下。适应性行为评估系统原始分数显示出最小的地板和天花板效应(<1-2.5%)。在线性回归模型中,得分与 6 岁以下的年龄相关(沟通,p=0.001;社交,p=0.003),但此后明显趋于平缓。得分因 DEE 组而异(均 p<0.001),且随着癫痫发作频率的增加而降低(沟通,p=0.01,社交,p=0.02)。与 mCHAT、CSBS 和 CM 评分具有良好的一致性(均 r>0.8)。

意义

原始分数和超出范围的 COA 可能提供敏感的测量值,适用于功能严重受损的 DEE 患者的非常有限的水平。为确保靶向试验结果对有意义的变化做出反应,开发这些方法对于针对罕见 DEE 的新型疗法的临床试验准备至关重要。

相似文献

1
Rare diseases - rare outcomes: Assessing communication abilities for the developmental and epileptic encephalopathies.罕见病——罕见结局:发育性和癫痫性脑病的沟通能力评估。
Epilepsy Behav. 2022 Mar;128:108586. doi: 10.1016/j.yebeh.2022.108586. Epub 2022 Feb 11.
2
Measuring the inch stones for progress: Gross motor function in the developmental and epileptic encephalopathies.衡量进展的里程碑:发育性和癫痫性脑病中的粗大运动功能
Epilepsy Behav. 2022 Dec;137(Pt A):108953. doi: 10.1016/j.yebeh.2022.108953. Epub 2022 Nov 9.
3
Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennox-Gastaut syndrome, ESES: A functional framework.Dravet 综合征、KCNQ2-DEE、KCNB1-DEE、Lennox-Gastaut 综合征、ESES 无癫痫发作后果:功能框架。
Epilepsy Behav. 2020 Oct;111:107287. doi: 10.1016/j.yebeh.2020.107287. Epub 2020 Aug 3.
4
SCN2A-Developmental and Epileptic Encephalopathies: Challenges to trial-readiness for non-seizure outcomes.SCN2A-发育性和癫痫性脑病:非癫痫结局临床试验准备的挑战。
Epilepsia. 2021 Jan;62(1):258-268. doi: 10.1111/epi.16750. Epub 2020 Nov 25.
5
Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials.由患者权益倡导者牵头的全球联盟,正在调整适用的结果指标,以确保发育性癫痫性脑病(DEEs)在临床试验中得到有意义的纳入。
Ther Adv Rare Dis. 2024 Jun 22;18:26330040241249762. doi: 10.1177/26330040241249762. eCollection 2024 Jan-Dec.
6
Evaluation of the Aberrant Behavior Checklist for Developmental and Epileptic Encephalopathies.发育性和癫痫性脑病异常行为检查表评估。
Epilepsy Behav. 2021 Jun;119:107958. doi: 10.1016/j.yebeh.2021.107958. Epub 2021 Apr 21.
7
Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children.儿童发育性和癫痫性脑病以及智力残疾和癫痫的流行病学。
Neurology. 2023 Mar 28;100(13):e1363-e1375. doi: 10.1212/WNL.0000000000206758. Epub 2022 Dec 29.
8
Dysautonomia and functional impairment in rare developmental and epileptic encephalopathies: the other nervous system.罕见发育性和癫痫性脑病中的自主神经功能障碍和功能障碍:另一种神经系统。
Dev Med Child Neurol. 2021 Dec;63(12):1433-1440. doi: 10.1111/dmcn.14990. Epub 2021 Jul 11.
9
KCNQ2-DEE: developmental or epileptic encephalopathy?KCNQ2相关发育性或癫痫性脑病:发育性还是癫痫性脑病?
Ann Clin Transl Neurol. 2021 Mar;8(3):666-676. doi: 10.1002/acn3.51316. Epub 2021 Feb 22.
10
Longitudinal assessment of adaptive behavior in infants and young children with newly diagnosed epilepsy: influences of etiology, syndrome, and seizure control.新诊断癫痫婴幼儿适应性行为的纵向评估:病因、综合征及癫痫控制的影响
Pediatrics. 2004 Sep;114(3):645-50. doi: 10.1542/peds.2003-1151-L.

引用本文的文献

1
Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome.用于Dravet综合征和Lennox-Gastaut综合征非癫痫症状的临床整体改善印象量表的开发与完善
J Patient Rep Outcomes. 2025 Feb 21;9(1):24. doi: 10.1186/s41687-024-00829-2.
2
Vagus nerve stimulation in Lennox-Gastaut syndrome: Twenty-four-month data and experience from the CORE-VNS study.迷走神经刺激治疗伦诺克斯-加斯东综合征:来自CORE-VNS研究的24个月数据及经验
Epilepsia. 2025 May;66(5):1540-1549. doi: 10.1111/epi.18289. Epub 2025 Feb 8.
3
A patient organization perspective: charting the course to a cure for SCN2A-related disorders.
患者组织视角:绘制治愈SCN2A相关疾病的路线图。
Ther Adv Rare Dis. 2024 Nov 11;5:26330040241292645. doi: 10.1177/26330040241292645. eCollection 2024 Jan-Dec.
4
Clinical trials for Lennox-Gastaut syndrome: Challenges and priorities.Lennox-Gastaut 综合征的临床试验:挑战与重点。
Ann Clin Transl Neurol. 2024 Nov;11(11):2818-2835. doi: 10.1002/acn3.52211. Epub 2024 Oct 23.
5
Assessing Communication Impairments in a Rare Neurodevelopmental Disorder: The Clinical Trials Readiness Study.评估一种罕见神经发育障碍中的沟通障碍:临床试验准备研究。
Neurol Clin Pract. 2025 Feb;15(1):e200391. doi: 10.1212/CPJ.0000000000200391. Epub 2024 Oct 18.
6
Parent-reported outcome measures evaluating communication in individuals with rare neurodevelopmental disorders: A systematic review.家长报告的结局评估工具在评估罕见神经发育障碍个体的沟通能力中的应用:系统综述。
Int J Lang Commun Disord. 2024 Nov-Dec;59(6):2528-2553. doi: 10.1111/1460-6984.13100. Epub 2024 Aug 14.
7
Expanded clinical phenotype spectrum correlates with variant function in SCN2A-related disorders.SCN2A相关疾病中扩展的临床表型谱与变异功能相关。
Brain. 2024 Aug 1;147(8):2761-2774. doi: 10.1093/brain/awae125.
8
Communication of individuals with CDKL5 deficiency disorder as observed by caregivers: A descriptive qualitative study.照顾者观察到的 CDKL5 缺乏症患者的沟通:一项描述性定性研究。
Am J Med Genet A. 2024 Jul;194(7):e63570. doi: 10.1002/ajmg.a.63570. Epub 2024 Feb 29.
9
FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies.FDA 患者为中心的药物开发指南:罕见发育性和癫痫性脑病临床试验准备的考虑因素。
Neurology. 2024 Jan 9;102(1):e207958. doi: 10.1212/WNL.0000000000207958. Epub 2023 Dec 15.
10
What does better look like in individuals with severe neurodevelopmental impairments? A qualitative descriptive study on SCN2A-related developmental and epileptic encephalopathy.严重神经发育障碍个体中“更好”的表现是什么?SCN2A 相关发育性和癫痫性脑病的定性描述性研究。
Qual Life Res. 2024 Feb;33(2):519-528. doi: 10.1007/s11136-023-03543-6. Epub 2023 Dec 8.